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Abstract
In many prokaryotes, the first step of threonine metabolism is catalysed by the
enzyme threonine dehydrogenase (TDH) which uses NAD+ to oxidise its sub-
strate to 2-amino-3-keto-butyrate. The absence of a functional TDH gene in
humans suggests that inhibitors of the enzyme may have therapeutic poten-
tial against pathogens which are reliant on this enzyme. We have cloned and
over-expressed TDH from Clostridium difficile and have determined the X-ray
structures of the apoenzyme form at 2.6 Å resolution.
1. Introduction
There are three known metabolic pathways of threonine catabolism, the initial
steps of which are catalysed by L-threonine aldolase (EC 4.1.2.5), L-threonine
dehydratase (also known as L-threonine deaminase; EC 4.2.1.16) and L-threonine
3-dehydrogenase (TDH; EC 1.1.1.103), the latter being the dominant pathway in
many species (Marcus & Dekker, 1993; Edgar, 2002). The activity of threonine
aldolase has been shown to be low or insignificant in prokaryotes (Lam et al.,
1980) and eukaryotes (Bird & Nunn, 1983), and no expression of the enzyme has
been detected in humans (Edgar, 2005). In contrast, the pathway initiated by
TDH is significant in many prokaryotes (Marcus & Dekker, 1993; Edgar, 2002)
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and becomes dominant in certain metabolic states in animals (Bird & Nunn,
1983). TDH is a mitochondrial matrix enzyme which uses NAD+ to oxidise
threonine to 2-amino-3-keto-butyrate (AKB) (Fig. 1). The second enzyme in
this pathway, 2-amino-3-keto-butyrate ligase (KBL, Schmidt et al., 2001), uses
coenzyme A to convert AKB to glycine and acetyl coenzyme A (Ac-CoA) (Fig.
1). This pathway plays a variety of roles in both prokaryotes and eukaryotes,
including energy production, homeostasis and fatty-acid synthesis (Millerioux et
al., 2013; Mazet et al., 2013).
Dehydrogenases are divided into short-, medium- and long-chain reductases
(SDRs, MDRs and LDRs, respectively) (Kavanagh et al., 2008). TDHs have
been found in the MDR family and these are tetrameric, having a requirement
for divalent metal cations, such as zinc (Boylan & Dekker, 1978, 1981; Bowyer
et al., 2009; Higashi et al., 2005; Ishikawa et al., 2007; Machielsen & van der
Oost, 2006). Other TDHs are found in the SDR family and are dimeric with no
requirement for metal ions (Yoneda et al., 2010, 2012; Ueatrongchit & Asano,
2011). They also have sequence and structural similarity with UDP-galactose
4’-epimerase (UDP-GalE).
The Ac-CoA produced by the TDH of the sleeping sickness parasite T. bru-
cei was shown to be of comparable importance for fatty-acid synthesis as that
produced by pyruvate dehydrogenase and inhibition of both enzymes is lethal
for the parasite (Millerioux et al., 2013; Mazet et al., 2013). In addition, the
glycine produced by the parasite TDH is incorporated into trypanothione, an
essential antioxidant. It has long been known that inhibition of the parasite
TDH by tetraethylthiuram disulfide (better known as the alcohol-aversion drug
antabuse) has trypanocidal effects (Cross et al.,1975; Linstead et al., 1977). The
absence of functional TDH in the human genome (Edgar, 2002) suggested that
its reliance on TDH may be an important achilles heel for the parasite and other
pathogens. This led us to express and crystallise the TDH enzymes from a range
of pathogenic species, including T. brucei for structure analysis and fragment
screening (Adjogatse et al., 2018).
In recent decades, the spore-forming bacterium Clostridium difficile has emerged
as a major cause of hospital-acquired infections of the colon that are associated
with prolonged antibiotic treatment and are increasing in mortality (Banawas,
2018). The rapid metabolism of threonine, and several other amino acids, by
clostridia suggested that the TDH from C. difficile is also of interest as a poten-
tial candidate for structure-based drug design, although clostridia appear capa-
ble of using all three alternative pathways of threonine metabolism (Fonknechten
et al., 2010; Neumann-Schaal et al., 2019). To this end we have cloned and over-
expressed the TDH from C. difficile and have determined the X-ray structures
of the apoenzyme form at 2.6 Å resolution.
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2. Methods
2.1. Cloning, expression and purification
The gene for the 318 amino acid SDR TDH from C. difficile (UniProt ID:
A0A4U8WM48 CLODI) was amplified from genomic DNA of strain 630∆erm
by PCR using KOD polymerase (Novagen) with forward and reverse primers
which were designed to introduce cleavage sites for the restriction enzymes NdeI
and BamHI and to convert the start codon from TTG to ATG:
Forward: gcgcctggatctagacatATGaaaaaaatacttataacaggtgc
Reverse: gcgcaagcttggatccgccctatttacctattcctttttctg
Following digestion of the amplified DNA with NdeI and BamHI, the TDH
gene was ligated with the expression vector pET16b using standard methods
and transformed into E. coli strains DH5α (for confirmatory sequencing) and
BL21(DE3) for expression of the deca-His-tagged enzyme. Primer synthesis and
plasmid sequencing were conducted by Yorkshire Bioscience, UK.
In order to obtain soluble C. difficile TDH enzyme, two steps were necessary.
Firstly, the cells were grown to mid-log phase at 310 Kelvin and then given a 25
min heat shock at 315 K followed by cooling on ice for 5 min prior to induction
with IPTG (0.3 mM) and shaking at 289 K for 2 days. Secondly, during nickel
affinity purification of the enzyme from the sonicated cell supernatant, the TDH
was eluted from the nickel column using 0.5 M imidazole in a single step into 50
mM Tris-HCl buffer at pH 7.5 containing 1 mM β-mercaptoethanol, 0.1 M NaCl
and 10 % glycerol. The enzyme was further equilibrated with the same buffer
by centrifugal ultra-filtration to remove the imidazole elutant and concentrate
the enzyme for crystal screening and storage at 253 K. The catalytic activity
was confirmed by mixing 1 µL enzyme with 25 µL of solution containing 50
mM threonine, 2 mM NAD+ and 200 mM Tris-HCl pH 8.4, and following the
decrease in absorbance at 340 nm with a Nanodrop ND-1000 spectrophotometer,
although the kinetic parameters of the enzyme were not determined.
2.2. Crystallisation
Screening for crystallisation conditions was undertaken by the vapour diffusion
method using 24-well hanging drop plates into which 0.7 ml of each of the
Molecular Dimensions Structure Screens I and II were pipetted. Siliconised glass
cover-slips, on which 5 µL of C. difficile TDH at a concentration of 5 mg/ml
were mixed with an equal volume of well solution, were inverted and sealed
above the wells with high vacuum grease (Dow Corning). The trays were left at
293 K and, after several days, large crystals appeared in 0.2 M lithium sulphate,
0.1 M Tris-HCl pH 8.5, 30 % v/v PEG 4000 (Structure Screen I, condition 35).
Subsequently crystals were found to grow in this condition with PEG 4000 in
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the concentration range 20 - 35 % v/v.
2.3. X-ray data collection and structure analysis
Crystals were transferred to 10 µL droplets of well solution using a cryoloop
(Molecular Dimensions) and four 1 µL droplets of glycerol were stirred in slowly
to cryoprotect the crystals prior to freezing in liquid nitrogen. Data were col-
lected from the crystals at 100 K at Diamond Light Source (DLS) beamline I04-1
using a PILATUS 2M detector and a wavelength of 0.92 Å. A total of 190◦ of data
were collected using a rotation range of 1◦ and an exposure time of 4 s per image.
The diffraction data were processed automatically at the beamline using MOS-
FLM (Battye et al., 2011) which suggested that the crystal was of the trigonal
point group 321 and the systematic absences along l indicated that the space
group was either P3121 or P3221. Scaling and merging of the data with Pointless
(Evans & Murshudov, 2013) followed by molecular replacement using MolRep
(Vagin & Teplyakov, 2010) with a monomer of T. brucei TDH (Adjogatse et
al., 2018) as the search model indicated that the correct choice of space group
was P3121. The crystals had unit cell dimensions of a, b=180.87 Å, c=88.35
Å, α, β=90.0◦, γ=120.0◦ and possessed 2 molecules per asymmetric unit with a
high solvent content of 78.9 % (Kantardjieff & Rupp, 2003). The structure was
rebuilt using Coot (Emsley et al., 2010) and refined using REFMAC (Murshu-
dov et al., 1997; 2011), both in the CCP4 suite (Winn et al., 2011). This process
also included one round of simulated annealing torsional molecular dynamics at
5000 K which was performed using CNS (Brünger et al., 1997). Data processing
and refinement statistics are shown in Table 1. Figures of the structure were
prepared using CueMol (http://www.cuemol.org/en).
3. Results
The structure of TDH from C. difficile has been determined at a resolution
2.6 Å and refined to an R-factor of 20.0 % and an R-free of 23.9 % (Table 1).
The tertiary structure is shown in Fig. 2. According to DynaRama (Casañal
et al., 2020) 85.8 % of the amino acids are in the most favoured region of the
Ramachandran plot.
A sequence alignment of C. difficile TDH with the enzymes from F. frigidi-
maris, T. volcanum, mouse M. musculus and T. brucei is shown in Fig. 3. These
short chain TDH enzymes have sequence identities of 48 %, 45 %, 41 % and 39
% with the C. difficile enzyme.
The enzyme consists of a Rossmann fold domain with some extensive elabo-
rations (predominantly at the C-terminal end of the protein) which create the
catalytic domain (Fig. 4). The first main elaboration follows the Rossmann fold
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strand β6 and consists of β7, α7, β8 and β9. The next two secondary struc-
ture elements, α8 and β10, appear to form part of the Rossmann fold domain
while the remainder of the protein forms the bulk of the catalytic domain. This
domain is substantially helical but contains two small sheet regions, the first of
which is parallel and is formed by β8 and β12 while the second one is formed
by β7, β9 and β11 with mixed topology.
The C. difficile TDH monomer superimposes on the the T. brucei enzyme
with an RMSD Cα deviation of 1.42 Å for 307 structurally equivalent residues
(Fig. 5). The dimers of these two enzymes superimpose with an RMSD of 1.71
Å demonstrating the strong conservation of quaternary structure (Fig. 6a). Use
of the EBI PISA server (Krissinel & Henrick, 2007) reveals that the dimer inter-
face of the C. difficile enzyme has a buried surface area of 1275 Å2 per monomer
and an estimated interaction energy of -13.5 kcal per mol. The interface occurs
between the Rossmann fold domains and involves 15 hydrogen bonds and 8 salt-
bridges. The contacts are predominantly formed by helices α5 and α6 from both
subunits, which are the largest helices in the molecule (Fig. 3) and show a high
degree of conservation (Fig. 6b).
The electrostatic surface of the dimer shows pronounced electropositive cavi-
ties which form the binding site for the phosphodiester of the NAD cofactor (Fig.
6c). The NAD cofactor and the competitive inhibitor pyruvate present in the T.
brucei complex (RCSB-ID: 5lc1) were used to indicate the position of the active
site residues (Fig. 7). Four residues making hydrogen bonds with the modelled
ligands were identified: Ser 80, Ser 117, Thr 184 and Tyr 142. Of these Ser 80
and Thr 184 are invariant (Fig. 3), Tyr 142 can be Phe and Ser 117 is conserva-
tively replaced by Thr in some TDH’s. The reaction involves the abstraction of
protons from the substrate Cβ carbon atom by the nicotinamide cofactor and
from the substrate hydroxyl group by a basic enzyme residue. On the basis of
other structures, it has been speculated that the conserved residues Tyr 142
and Ser/Thr 117 could perform this role (Adjogatse et al., 2018; Yoneda et al.,
2012). This tyrosine residue is part of a YGxxK motif (Fig. 3) which includes
an invariant lysine that has been hypothesised to play a part in the transfer of
the proton (e.g. Adjogatse et al., 2017), although in the C. difficile apo-TDH
structure, the sidechain of this residue (Lys 146) points away from the predicted
substrate binding site.
The loop between Thr 177 and Thr 183 immediately precedes the active site
residue Thr 184 and is rich in the flexible amino acid glycine. This loop is
shown on the lower-right of Fig. 7 close to the predicted position of the inhibitor
pyruvate. In the T. brucei enzyme, this loop was found to occupy two posi-
tions depending on whether cofactor was bound or not (Adjogatse et al., 2018).
Comparison of the two structures demonstrates that this loop is in the open
conformation in C. difficile apo-TDH, which is consistent with the absence of
the co-factor or an inhibitor in our structure. Interestingly, there is some elec-
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tron density for the closed conformation of this loop in the vicinity of Thr 183
suggesting an alternative location for the preceding glycine residue (Gly 182).
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Table 1. X-ray data collection, processing and refinement statistics. The values in




a, b (Å) 180.87
c (Å) 88.35
α, β, γ (◦) 90, 90, 120
Solvent content (%) 78.9
N o molecules per asymmetric unit 2
Matthews coefficient (Å3 Da−1) 5.8
Mosaic spread (◦) 0.36
Resolution (Å) 63.2-2.6 (2.7-2.6)
∗Rmerge (%) 11.8 (177.8)
#Rmeas (%) 12.5 (189.7)
$CC1/2 (%) 99.8 (52.6)
Average I/σ(I) 12.2 (1.1)
Multiplicity 9.3 (8.3)
N o observed reflections 498,386 (64,046)
N o unique reflections 53,475 (7,758)
Wilson plot B -factor (Å2) 61.4
R-factor (%) 20.0
Free R-factor (%) 23.9
N o reflections in work/test sets 49,943/2,500
RMSD bond lengths (Å) 0.0094
RMSD bond angles (◦) 1.790
Mean protein B -factor (Å2) 80.6
∗Rmerge = ΣhklΣi|Ii(hkl)− < I(hkl) > |/ΣhklΣiIi(hkl)
#Rmeas = Σhkl{N(hkl)/[N(hkl)− 1]}
1/2Σi|Ii(hkl)− < I(hkl) > |/ΣhklΣiIi(hkl)
$ Half-set correlation coefficient (Karplus & Diederichs, 2012).
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Fig. 1. The reaction catalysed by L-threonine dehydrogenase.
Fig. 2. The 3D structure of L-threonine dehydrogenase from C. difficile at 2.6
Å resolution.
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Fig. 3. A sequence alignment of C. difficile TDH with the enzymes from F.
frigidimaris, T. volcanum, mouse (M. musculus) and T. brucei. The amino
acids are coloured according to the scheme: acidic: red, basic: pale-blue,
neutral-polar: green, hydrophobic: purple, cysteine: yellow and the struc-
turally important residues Gly, Ala, Pro: white. The numbers shown cor-
respond to the combined alignment. The residues involved in substrate and
inhibitor binding in related TDH’s (Ser 80, Tyr 142 and Thr 184, in C. diffi-
cile numbering) are shown boxed at positions 91, 154 and 196. Note that the
tyrosine is not invariant. The secondary structure elements of the protein are
labelled and displayed with a similar colour scheme to Fig. 2. This figure was
prepared using Alscript (Barton, 1993).
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Fig. 4. The two domains of TDH. The Rossmann fold domain which is formed
predominantly by the N-terminal portion of the protein is coloured blue and
the C-terminal catalytic domain is shown red.
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Fig. 5. A superposition of C. difficile TDH (beige) with the T. brucei enzyme
(pale blue). The NAD cofactor and the competitive inhibitor pyruvate in the
T. brucei complex (RCSB-ID: 5lc1) are shown in ball-and-stick representation
to indicate the position of the active site.
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Fig. 6a. A superposition of the C. difficile TDH dimer (beige) with that of the T.
brucei enzyme (pale blue) demonstrates the strong conservation of the dimeric
quaternary structure. The NAD cofactor and inhibitor pyruvate bound to the
T. brucei enzyme are also shown.
Fig. 6b. The C. difficile TDH dimer coloured according to the conservation of the
amino acid sequences shown in Fig. 3. Blue indicates the strongly conserved
regions while beige indicates the most variable. The sequence conservation
in the vicinity of helices which form the dimer interface is apparent. The
conservation analysis was done using ProtSkin (Ritter et al., 2004).
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Fig. 6c. The C. difficile solvent accessible surface of the C. difficile TDH dimer
coloured according to electrostatic potential. The basic nature of the NAD
binding site is visible for the left-hand monomer (red: acidic, blue: basic). The
NAD and pyruvate inhibitor present in the T. brucei structure are also shown.
IUCr macros version 2.1.11: 2020/04/29
16
Fig. 7. The active site of C. difficile TDH. The side chains of the residues Ser
80, Ser 117, Tyr 142 and Thr 184 which are within hydrogen-bonding distance
of the pyruvate present in the T. brucei TDH structure are labelled. The T
brucei pyruvate and NAD are shown with grey carbon atoms.
Synopsis
We have cloned, expressed and crystallised the threonine dehydrogenase from Clostridium
difficile and have determined the X-ray structure of the apoenzyme form at 2.6 Å resolution
with an R-factor of 20.0 % and an R-free of 23.9 %.
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